References
1. Yang, S., Tsiatis, A. A. &
Blazing, M. Modeling survival distribution as a function of time to
treatment discontinuation: A dynamic treatment regime approach.Biometrics 74, 900–909 (2018).
2. Gong, Y. et al. Time
to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic
non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials.Journal of Clinical Oncology vol. 36 9064–9064 (2018).
3. Walker, M. S., Herms, L. &
Miller, P. J. E. Performance of time to discontinuation and time to next
treatment as proxy measures of progression-free survival, overall and by
treatment group. Journal of Clinical Oncology vol. 38
e19135–e19135 (2020).
4. Ramakrishnan, K. et
al. Real-world time on treatment with immuno-oncology therapy in
recurrent/metastatic head and neck squamous cell carcinoma. Future
Oncol. 17, 3037–3050 (2021).
5. Velcheti, V. et al.Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy
for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data.Cancers vol. 14 1041 (2022).
6. Weis, T. M., Hough, S.,
Reddy, H. G., Daignault-Newton, S. & Kalemkerian, G. P. Real-world
comparison of immune checkpoint inhibitors in non-small cell lung cancer
following platinum-based chemotherapy. J. Oncol. Pharm. Pract.26, 564–571 (2020).
7. Bauml, J. et al.Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck
Cancer: Results From a Single-Arm, Phase II Study. J. Clin.
Oncol. 35, 1542–1549 (2017).
8. Blumenthal, G. M. et
al. Analysis of time-to-treatment discontinuation of targeted therapy,
immunotherapy, and chemotherapy in clinical trials of patients with
non-small-cell lung cancer. Ann. Oncol. 30, 830–838
(2019).
9. Stewart, M. et al.An Exploratory Analysis of Real-World End Points for Assessing Outcomes
Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung
Cancer. JCO Clin Cancer Inform 3, 1–15 (2019).
10. Royston, P. & Parmar, M.
K. B. Restricted mean survival time: an alternative to the hazard ratio
for the design and analysis of randomized trials with a time-to-event
outcome. BMC Medical Research Methodology vol. 13 (2013).
11. Lopes, G. et al.Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as
first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor
proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.Journal of Clinical Oncology vol. 36 LBA4–LBA4 (2018).
12. Argiris, A. & Johnson, J.
Faculty Opinions recommendation of Pembrolizumab for Platinum- and
Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm,
Phase II Study. Faculty Opinions – Post-Publication Peer Review
of the Biomedical Literature (2017)
doi:10.3410/f.727429341.793534852.
13. Kaplan, E. L. & Meier, P.
Nonparametric Estimation from Incomplete Observations. Springer
Series in Statistics 319–337 (1992)
doi:10.1007/978-1-4612-4380-9_25.
14. Guan, Y. et al. A
survival model generalized to regression learning algorithms. Nat
Comput Sci 1, 433–440 (2021).
15. Suthaharan, S. Support
Vector Machine. Machine Learning Models and Algorithms for Big
Data Classification 207–235 (2016)
doi:10.1007/978-1-4899-7641-3_9.
16. Flatiron Health.Flatiron Health https://flatiron.com/
(2017).